TIL-based Therapies Market, 2021-2030 by Roots Analysis
Driven by
the potential to confer sustained therapeutic effects and thereby, facilitate
prolonged periods of remission, TIL-based therapies have received significant
financial support, and promising leads are poised to soon achieve blockbuster
status
Roots Analysis has announced the addition of “TIL-based Therapies Market,
2021-2030” report to its list of
offerings.
Given the frequently reported inadequacies of
conventional cancer therapies and the growing need for personalized medicine,
there is a marked surge in the demand for TIL-based therapies. In addition, the
clinical success in this domain is likely to draw in investments that will
support ongoing and anticipated therapy development initiatives.
To order this 255+ page report, which features 90+ figures and 100+ tables, please visit
https://www.rootsanalysis.com/reports/til-therapies-market.html
Key Market Insights
Over 80 TIL-based therapies are
currently under development
Close
to 55% of the aforementioned candidates are being evaluated in clinical stages
(phase I/II and above), while more than 20% therapies are in preclinical
and discovery stages. Examples of late-stage clinical candidates include
CCRT+TIL, Lifileucel, LTX-315 and TILs, and IOV-2001 and LN-145.
More than 80% pipeline candidates are presently being
developed to target solid tumors
T-cell immunotherapy developers were observed to be
primarily focused on the treatment of different oncological indications. It is
worth noting that 17% pipeline candidates are being developed for the treatment
of both hematological and solid tumors.
Partnership activity
within this domain has increased at a CAGR of 45%, between 2011 and 2020
The maximum partnerships related to TIL-based therapies
were inked in the period 2017-2019. Majority of partnership deals signed within
this domain were R&D agreements (33%), followed by technology licensing
(20%) and manufacturing (15%) agreements.
Over USD 2 billion has been invested by both private and
public investors, across 30 instances
It is important to mention that, between 2013 and 2020,
majority of the funding amount was raised through other equity financing
elements (33%), venture capital rounds (30%) and secondary offerings (20%).
This market is
anticipated to grow at a CAGR of 60.6%, during the period 2021-2030
Growth in this domain is
anticipated to be primarily driven by encouraging clinical trial results and
likely approval of some advanced stage therapy candidates. Further, North
America (primarily the US) and Europe are expected to capture over 90%
of the market share (in terms of sales-based revenues) by 2030.
To request a sample
copy / brochure of this report, please visit
https://www.rootsanalysis.com/reports/til-therapies-market.html
Key
Questions Answered
§
What are the prevalent R&D trends related to TIL-based
therapies?
§
Who are the leading industry and non-industry players
engaged in the development of TIL-based therapies?
§
What challenges are commonly faced by stakeholders engaged
in this domain?
§
Who are the key investors in this domain?
§
Who are the key opinion leaders / experts engaged in this
upcoming field of therapeutics?
§
Which types of partnership models are commonly adopted by
industry stakeholders?
§
Which regions are key contract manufacturing hubs for
TIL-based therapies?
§
Which factors are likely to influence the evolution of this
upcoming market?
§
How is the current and future market opportunity likely to
be distributed across key market segments?
The USD 4.3+ billion (by 2030) financial opportunity within the
TIL-based therapies market has been analyzed across the following segments:
§
Target Indication
§
Acute Lymphoblastic Leukemia
§
Melanoma
§
Others
§
Key Players
§
Key Geographical Regions
§
North America
§
Europe
§
Asia Pacific
The research includes brief profiles, featuring an overview
of the company, its financial information (if available), details
related to its product(s), highlighting type of therapy and current development
status, technology portfolio (if available), recent developments and
manufacturing capabilities.
§
Cellular Biomedicine Group
§
Iovnace Biotherapeutics
§
Lytix Biopharma
§
Phio Pharmaceuticals
For additional
details, please visit
https://www.rootsanalysis.com/reports/til-therapies-market.html or
email sales@rootsanalysis.com
You may also be
interested in the following titles:
1.
Global T-Cell Therapies Market (5th Edition): Industry
Trends and Global Forecasts, 2021-2030
2.
CAR-T Cell Therapies
Market
(3rd Edition): Industry Trends and Global Forecasts, 2021-2030
3.
TCR-based Therapies
Market:
Industry Trends and Global Forecasts, 2021-2030
4.
Cell and Gene Therapy
CROs Market:
Industry Trends and Global Forecasts (2nd Edition), 2021-2030
5.
Gene Therapy Market (4th Edition): Industry
Trends and Global Forecasts, 2020-2030
About Roots Analysis
Roots Analysis is one of the fastest growing
market research companies, sharing fresh and independent perspectives in the
bio-pharmaceutical industry. The in-depth research, analysis and insights are
driven by an experienced leadership team which has gained many years of
significant experience in this sector. If you’d like help with your growing
business needs, get in touch at info@rootsanalysis.com
Contact Information
Roots
Analysis Private Limited
Gaurav Chaudhary
+1 (415) 800 3415
Facebook - https://www.facebook.com/RootsAnalysis
LinkedIn - https://www.linkedin.com/company/roots-analysis/mycompany/
Twitter - https://twitter.com/RootsAnalysis
Comments
Post a Comment